Strides Pharma and Incepta Forge Alliance to Transform Contraceptive Access in Africa

In a landmark move set to significantly impact public health across the African continent, Strides Pharma Science Ltd. has announced a powerful partnership with Bangladesh’s leading pharmaceutical giant, Incepta Pharmaceuticals Ltd. This strategic collaboration is poised to introduce a crucial long-acting injectable contraceptive, offering a new beacon of hope for enhanced family planning and sexual health services in numerous African nations.

The core of this alliance lies in bringing a high-quality, long-acting injectable contraceptive—a product equivalent to established options like Depo-Provera and Sayana Press—to regions where such access is often limited.

Incepta Pharmaceuticals, renowned for its manufacturing prowess, will be the exclusive producer of this vital contraceptive. Meanwhile, Strides Pharma Science will leverage its robust market presence and extensive distribution network across Africa to ensure the product reaches those who need it most.

This initiative is not merely a business venture; it represents a profound commitment to addressing the substantial unmet needs in sexual and reproductive health (SRH) that persist across many African communities.

By providing a reliable, long-acting contraceptive option, the partnership aims to empower individuals with greater control over their reproductive choices, contributing to healthier families and more sustainable community development.

A cornerstone of this collaboration's credibility and potential impact is the product's registration under the World Health Organization (WHO) Prequalification Programme.

This rigorous certification ensures that the contraceptive meets stringent global standards for quality, safety, and efficacy, instilling confidence among healthcare providers and recipients alike. The WHO Prequalification acts as a vital endorsement, facilitating broader acceptance and quicker integration into national health programs.

Strides Pharma’s strategic focus on the African market, combined with Incepta’s manufacturing excellence and the WHO's stamp of approval, creates a formidable force for change.

The company has a proven track record in the region, making it an ideal partner for the successful launch and sustained availability of this essential medicine. This partnership underscores a shared vision: to expand access to life-changing pharmaceutical solutions, fostering better health outcomes and a brighter future for communities throughout Africa.

As this partnership unfolds, it is expected to significantly bolster family planning initiatives, reduce unintended pregnancies, and improve maternal and child health indicators.

The introduction of this accessible, long-acting contraceptive stands as a testament to the power of international collaboration in tackling global health challenges and making a tangible difference in people's lives.